{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:48:21Z","timestamp":1788904101884,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shandong Natural Science Foundation Innovation and Development Joint Fund","award":["ZR2022LSW008"],"award-info":[{"award-number":["ZR2022LSW008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder urothelial carcinoma (BLCA) is the most common malignancy of the urinary tract, presenting with a wide range of clinical symptoms and prognosis. Disulfidptosis is a newly identified cell death method and closely associated with BLCA progression, prognosis, and treatment outcome. Currently, we need to construct a new prognostic model for disulfidptosis-related long noncoding RNAs (drlncRNAs) to improve the treatment strategy of BLCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The data for BLCA samples were obtained from The Cancer Genome Atlas (TCGA), and then 10 unique genes related to disulfidoptosis (DRGs) were identified from research papers. The differences between the two groups showed in this study were used to create the \u201cdisulfidptosis-related long noncoding RNAs score\u201d (disulfidptosis-score) prognostic model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified two groups of drlncRNAs with high and low disulfidptosis scores in this study. Patients with low disulfidptosis scores had a better overall survival rate compared to those with high scores in bladder cancer, and the high disulfidptosis score subtype exhibited more active malignant pathways related to cancer than the low score subtype. We found that the low disulfidptosis-score subgroup had better prognosis than the high disulfidptosis-score subgroup. The expression of mutation burden was much higher in the low disulfidptosis-score group than in the high disulfidptosis-score group. The low disulfidptosis-score subgroup of patients exhibited significantly higher proportions of plasma cells, T cells CD8, and Tregs, while the high-risk subgroup had a greater abundance of Macrophages M0 and Macrophages M2. The disulfidptosis-score showed a strong correlation with the sensitivity of chemotherapeutic drugs, and patients in the low disulfidptosis-score group were more likely to exhibit an immune response and respond positively to immunotherapy. Additionally, we developed a nomogram to enhance the accuracy of the disulfidptosis-clinical score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on our investigation of disulfidptosis-score in BLCA, disulfidptosis-score may have an important role in TME, prognosis, and drug sensitivity. We also investigated the significance of the disulfidoptosis-score in relation to immunotherapy and immune response, providing a basis for improving prognosis and responding to immunotherapy among patients with BLCA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-024-01454-3","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T05:03:15Z","timestamp":1711429395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature"],"prefix":"10.1186","volume":"24","author":[{"given":"Chao","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanpeng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"issue":"16","key":"1454_CR1","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1002\/cncr.33587","volume":"127","author":"F Bray","year":"2021","unstructured":"Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029\u201330. https:\/\/doi.org\/10.1002\/cncr.33587.","journal-title":"Cancer"},{"issue":"19","key":"1454_CR2","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, et al. Bladder Cancer: Rev JAMA. 2020;324(19):1980\u201391. https:\/\/doi.org\/10.1001\/jama.2020.17598.","journal-title":"Bladder Cancer: Rev JAMA"},{"key":"1454_CR3","doi-asserted-by":"publisher","unstructured":"Zucchi A, Claps F, Pastore AL, et al. Focus on the use of resveratrol in bladder Cancer. Int J Mol Sci. 2023;24(5). https:\/\/doi.org\/10.3390\/ijms24054562.","DOI":"10.3390\/ijms24054562"},{"issue":"8","key":"1454_CR4","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","volume":"38","author":"A Richters","year":"2020","unstructured":"Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895\u2013904. https:\/\/doi.org\/10.1007\/s00345-019-02984-4.","journal-title":"World J Urol"},{"key":"1454_CR5","doi-asserted-by":"publisher","first-page":"1163115","DOI":"10.3389\/fphar.2023.1163115","volume":"14","author":"C Zhang","year":"2023","unstructured":"Zhang C, Xiao J, Yuan T, et al. Molecular vasculogenic mimicry-related signatures predict clinical outcomes and therapeutic responses in bladder cancer: results from real-world cohorts. Front Pharmacol. 2023;14:1163115. https:\/\/doi.org\/10.3389\/fphar.2023.1163115.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1454_CR6","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1002\/tox.24066","volume":"39","author":"Z Li","year":"2024","unstructured":"Li Z, Li Y, Liu L, et al. Multiple programmed cell death patterns and immune landscapes in bladder cancer: evidence based on machine learning and multi-cohorts. Environ Toxicol. 2024;39(3):1780\u2013801. https:\/\/doi.org\/10.1002\/tox.24066.","journal-title":"Environ Toxicol"},{"issue":"3","key":"1454_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41556-023-01091-2","volume":"25","author":"X Liu","year":"2023","unstructured":"Liu X, Nie L, Zhang Y, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat Cell Biol. 2023;25(3):404\u201314. https:\/\/doi.org\/10.1038\/s41556-023-01091-2.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"1454_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41556-023-01100-4","volume":"25","author":"LM Machesky","year":"2023","unstructured":"Machesky LM. Deadly actin collapse by disulfidptosis. Nat Cell Biol. 2023;25(3):375\u20136. https:\/\/doi.org\/10.1038\/s41556-023-01100-4.","journal-title":"Nat Cell Biol"},{"key":"1454_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. BMC Bioinformatics. 2013;14:7. https:\/\/doi.org\/10.1186\/1471-2105-14-7. GSVA: gene set variation analysis for microarray and RNA-seq data."},{"key":"1454_CR10","doi-asserted-by":"publisher","first-page":"951214","DOI":"10.3389\/fimmu.2022.951214","volume":"13","author":"TK Mak","year":"2022","unstructured":"Mak TK, Li X, Huang H, et al. The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer. Front Immunol. 2022;13:951214. https:\/\/doi.org\/10.3389\/fimmu.2022.951214.","journal-title":"Front Immunol"},{"key":"1454_CR11","doi-asserted-by":"publisher","unstructured":"Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6). https:\/\/doi.org\/10.1093\/bib\/bbab260.","DOI":"10.1093\/bib\/bbab260"},{"issue":"8","key":"1454_CR12","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","volume":"26","author":"A Iasonos","year":"2008","unstructured":"Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364\u201370. https:\/\/doi.org\/10.1200\/JCO.2007.12.9791.","journal-title":"J Clin Oncol"},{"issue":"7679","key":"1454_CR13","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1038\/551S33a","volume":"551","author":"MB Grayson","year":"2017","unstructured":"Grayson MB. cancer Nat. 2017;551(7679):S33. https:\/\/doi.org\/10.1038\/551S33a.","journal-title":"cancer Nat"},{"key":"1454_CR14","doi-asserted-by":"publisher","first-page":"990326","DOI":"10.3389\/fgene.2022.990326","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li X, Li X, et al. Comprehensive analysis of cuproptosis-related long noncoding RNA immune infiltration and prediction of prognosis in patients with bladder cancer. Front Genet. 2022;13:990326. https:\/\/doi.org\/10.3389\/fgene.2022.990326.","journal-title":"Front Genet"},{"issue":"1","key":"1454_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13046-023-02675-4","volume":"42","author":"P Zheng","year":"2023","unstructured":"Zheng P, Zhou C, Ding Y, et al. Disulfidptosis: a new target for metabolic cancer therapy. J Exp Clin Cancer Res. 2023;42(1):103. https:\/\/doi.org\/10.1186\/s13046-023-02675-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"1454_CR16","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.2147\/CMAR.S305547","volume":"13","author":"X Han","year":"2021","unstructured":"Han X, Liu J, Liu Y, et al. LINC-PINT inhibited malignant progression of bladder Cancer by targeting miR-155-5p. Cancer Manag Res. 2021;13:4393\u2013401. https:\/\/doi.org\/10.2147\/CMAR.S305547.","journal-title":"Cancer Manag Res"},{"key":"1454_CR17","doi-asserted-by":"publisher","first-page":"9316847","DOI":"10.1155\/2022\/9316847","volume":"2022","author":"J Liu","year":"2022","unstructured":"Liu J, Cui J, Zhao S, et al. Ferroptosis-related long noncoding RNAs have excellent predictive ability for multiomic characteristics of bladder Cancer. Oxid Med Cell Longev. 2022;2022:9316847. https:\/\/doi.org\/10.1155\/2022\/9316847.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"1454_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.yexcr.2019.03.009","volume":"378","author":"R Li","year":"2019","unstructured":"Li R, Zhang L, Qin Z, et al. High LINC00536 expression promotes tumor progression and poor prognosis in bladder cancer.Exp. Cell Res. 2019;378(1):32\u201340. https:\/\/doi.org\/10.1016\/j.yexcr.2019.03.009.","journal-title":"Cell Res"},{"issue":"10","key":"1454_CR19","doi-asserted-by":"publisher","first-page":"300060521104994","DOI":"10.1177\/03000605211049946","volume":"49","author":"J Luo","year":"2021","unstructured":"Luo J, Xu J, Ou L, et al. Role of hypermethylated-lncRNAs in the prognosis of bladder cancer patients. J Int Med Res. 2021;49(10):3000605211049946. https:\/\/doi.org\/10.1177\/03000605211049946.","journal-title":"J Int Med Res"},{"key":"1454_CR20","doi-asserted-by":"publisher","first-page":"647236","DOI":"10.3389\/fonc.2021.647236","volume":"11","author":"J Wan","year":"2021","unstructured":"Wan J, Guo C, Fang H, et al. Autophagy-related long non-coding RNA is a Prognostic Indicator for bladder Cancer. Front Oncol. 2021;11:647236. https:\/\/doi.org\/10.3389\/fonc.2021.647236.","journal-title":"Front Oncol"},{"key":"1454_CR21","doi-asserted-by":"publisher","first-page":"1027449","DOI":"10.3389\/fimmu.2022.1027449","volume":"13","author":"Y Bai","year":"2022","unstructured":"Bai Y, Zhang Q, Liu F, et al. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer. Front Immunol. 2022;13:1027449. https:\/\/doi.org\/10.3389\/fimmu.2022.1027449.","journal-title":"Front Immunol"},{"issue":"10","key":"1454_CR22","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9.","journal-title":"Lancet Oncol"},{"key":"1454_CR23","doi-asserted-by":"publisher","first-page":"590618","DOI":"10.3389\/fimmu.2020.590618","volume":"11","author":"X Wu","year":"2020","unstructured":"Wu X, Lv D, Cai C, et al. A TP53-Associated Immune Prognostic signature for the prediction of overall survival and therapeutic responses in muscle-invasive bladder Cancer. Front Immunol. 2020;11:590618. https:\/\/doi.org\/10.3389\/fimmu.2020.590618.","journal-title":"Front Immunol"},{"key":"1454_CR24","doi-asserted-by":"publisher","first-page":"704712","DOI":"10.3389\/fgene.2021.704712","volume":"12","author":"H Xiao","year":"2021","unstructured":"Xiao H, Huang W, Li Y, et al. Targeting long non-coding RNA TTN-AS1 suppresses bladder Cancer Progression. Front Genet. 2021;12:704712. https:\/\/doi.org\/10.3389\/fgene.2021.704712.","journal-title":"Front Genet"},{"key":"1454_CR25","doi-asserted-by":"publisher","unstructured":"Chen B, Khodadoust MS, Liu CL et al. Profiling Tumor infiltrating Immune cells with CIBERSORT.Methods Mol Biol.2018;1711:243\u201359. https:\/\/doi.org\/10.1007\/978-1-4939-7493-1_12.","DOI":"10.1007\/978-1-4939-7493-1_12"},{"issue":"6","key":"1454_CR26","doi-asserted-by":"publisher","first-page":"e12926","DOI":"10.1111\/sji.12926","volume":"92","author":"D Krantz","year":"2020","unstructured":"Krantz D, Mints M, Winerdal M, et al. IL-16 processing in sentinel node regulatory T cells is a factor in bladder cancer immunity. Scand J Immunol. 2020;92(6):e12926. https:\/\/doi.org\/10.1111\/sji.12926.","journal-title":"Scand J Immunol"},{"issue":"5","key":"1454_CR27","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00345-020-03474-8","volume":"39","author":"JL Pfail","year":"2021","unstructured":"Pfail JL, Katims AB, Alerasool P, et al. Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions. World J Urol. 2021;39(5):1319\u201329. https:\/\/doi.org\/10.1007\/s00345-020-03474-8.","journal-title":"World J Urol"},{"issue":"5","key":"1454_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00345-020-03498-0","volume":"39","author":"M Rouanne","year":"2021","unstructured":"Rouanne M, Radulescu C, Adam J, et al. PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. World J Urol. 2021;39(5):1345\u201355. https:\/\/doi.org\/10.1007\/s00345-020-03498-0.","journal-title":"World J Urol"},{"issue":"20","key":"1454_CR29","doi-asserted-by":"publisher","first-page":"7729","DOI":"10.1002\/cam4.3400","volume":"9","author":"Y Wang","year":"2020","unstructured":"Wang Y, Chen L, Yu M, et al. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer. Cancer Med. 2020;9(20):7729\u201341. https:\/\/doi.org\/10.1002\/cam4.3400.","journal-title":"Cancer Med"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01454-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-024-01454-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01454-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T05:04:46Z","timestamp":1711429486000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-024-01454-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1454"],"URL":"https:\/\/doi.org\/10.1186\/s12894-024-01454-3","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}],"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3078929\/v1","asserted-by":"object"}]},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"18 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The summary statistics are publicly downloadable in the website. All of these data are de-identified, freely downloadable, and can be used without restriction. Due to such a re-analysis of previously collected and published data, no additional ethics approval was needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}